Medicine and Dentistry
Primary Prevention
100%
Atrial Fibrillation
100%
Randomized Controlled Trial
100%
Gemfibrozil
100%
Electrocardiogram
55%
Peroxisome Proliferator Activated Receptor
44%
Placebo
33%
Ischemic Heart Disease
22%
Proportional Hazards Model
22%
Secondary Prevention
11%
Oxidative Stress
11%
Hazard Ratio
11%
Veterans Affairs
11%
High Density Lipoprotein Cholesterol
11%
Intervention Trial
11%
Post-Hoc Analysis
11%
Antiarrhythmic Drug
11%
Keyphrases
Primary Prevention
100%
Atrial Fibrillation
100%
Randomized Controlled Trial
100%
Gemfibrozil
100%
Peroxisome Proliferator-activated Receptor
44%
Inflammation
22%
Placebo
22%
Coronary Artery Disease
22%
Cox Regression
22%
Oxidative Stress
11%
Risk Factors
11%
Clinical Data
11%
Intervention Studies
11%
Hazard Ratio
11%
Veterans Affairs
11%
Relative Risk
11%
High-density Lipoprotein Cholesterol (HDL-C)
11%
Clinically Indicated
11%
Competing Risks
11%
Secondary Prevention Trials
11%
Placebo Groups
11%
Nursing and Health Professions
Primary Prevention
100%
Gemfibrozil
100%
Atrial Fibrillation
100%
Efficacy
100%
Electrocardiogram
55%
Peroxisome Proliferator Activated Receptor
44%
Placebo
33%
Inflammation
22%
Proportional Hazards Model
22%
Ischemic Heart Disease
22%
Hazard Ratio
11%
Secondary Prevention
11%
Post Hoc Analysis
11%
High Density Lipoprotein Cholesterol
11%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Atrial Fibrillation
100%
Gemfibrozil
100%
Peroxisome Proliferator Activated Receptor
44%
Placebo
33%
Inflammation
22%
Ischemic Heart Disease
22%
Intervention Trial
11%
Antiarrhythmic Drug
11%
High Density Lipoprotein Cholesterol
11%